Altogether, our data reveal that PDX-3101 responds to treatment with RGS but has an “immunologically cold” TME, lacking sufficient CD8+ T cells to respond to anti-PD-1, which likely contributed to the resistance of this PDX tumor to anti-PD-1 therapies. This evidence concerns the gene CD8A and neoplasm.